luminex multiplex assays discovery technologies k...confluence discovery technologies, inc. 4320...
TRANSCRIPT
Luminex Multiplex
Assays
Applications include:
Signal transduction path way evaluation
Sample Sources: Tissue culture conditioned media, whole blood / isolated PBMC, serum/plasma, biological fluids
Species: human, mouse, rat, canine, non-human primate
Analytes: Signaling proteins (phospho and total), Cytokines, Chemokines
Data Generation: Concentration (cytokine, chemokine and signal ing molecules), IC
50
determination
ROCK
Rho
FAK CrK
Pax PYK2
GTP Gα-O
GEFs
CDC42 Rac
MEKs
PAK MKKs
ASK1
JNK
P38 IP3R
PKC
BIMP1
BCL10
NFκB IκBs
P
IKKs
IκBsDegradation
Src
SOSGRB2SHC
RasGEFs
Raf1
MEKs
ERKs
PLC-β
DAG
NFκB
IKKs
PκB
IP3
Ca+2Ca+2
Ca+2
Calm
P
Caln
NFAT
NFAT
P
PI3K
Gβ Gγ
LARG
BRaf
MEKs
ERKs
cAMP
EPACPKA
PDZRhoGEF
Gα-1 GTP
Rap1
p115RhoGEF
RT
KS
CREB
Gα12/13
SRF
GTP
CREB
SRF ELK-1
c-Jun
c-Fos
STAT
NFκBNFAT
Gene Expression
Gα Gβ
© 2013 CDT all rights reserved
CON
LFU
ENCE
DIS
COVE
RY T
ECH
NO
LOG
IES
| TE
CHN
ICAL
BRI
EFTECHNICAL BRIEF:
Luminex Multiplex AssaysD I S C O V E R Y T E C H N O L O G I E S
As the information around signaling pathways and poten-
tially drugable targets expands, there is increasing pressure
to quickly probe these pathways. There is a greater need to
understand the nature of protein-protein interactions within
signaling pathways and to identify biomarkers of metabolic
processes. Singleplex detection methods such as ELISA or
Western blot assays are not suitable for rapid investigation
of complex signaling pathways composed of several mem-bers. Luminex technology offers the ability to multiplex
detection of several proteins from a single biological sample.
The open architecture of Luminex technology allows for
multiplexing of many types of assays thus reducing time,
labor, and costs over traditional methods.
Applications The Confluence Discovery Technologies team has a wide range of experience in developing and validating Luminex Multiplex assays to suit many different requirements. Our highly trained and knowledgeable scientists will assist with experimental design to develop and validate assays to meet client-specified criteria. We also perform data analysis and interpretation of Luminex Multiplex data to enable our clients to obtain the best insights from large, complex data outputs.
ROCK
Rho
FAK CrK
Pax PYK2
GTP Gα-O
GEFs
CDC42 Rac
MEKs
PAK MKKs
ASK1
JNK
P38 IP3R
PKC
BIMP1
BCL10
NFκB IκBs
P
IKKs
IκBsDegradation
Src
SOSGRB2SHC
RasGEFs
Raf1
MEKs
ERKs
PLC-β
DAG
NFκB
IKKs
PκB
IP3
Ca+2Ca+2
Ca+2
Calm
P
Caln
NFAT
NFAT
P
PI3K
Gβ Gγ
LARG
BRaf
MEKs
ERKs
cAMP
EPACPKA
PDZRhoGEF
Gα-1 GTP
Rap1
p115RhoGEF
RT
KS
CREB
Gα12/13
SRF
GTP
CREB
SRF ELK-1
c-Jun
c-Fos
STAT
NFκBNFAT
Gene Expression
Gα Gβ
© 2013 CDT all rights reserved
CDTv1.8.13
Confluence Discovery Technologies, Inc.4320 Forest Park Avenue
Saint Louis, MO 63108Phone: 314-932-4032 x305
Fax: 314-932-4038www.confluencediscovery.com
D I S C O V E R Y T E C H N O L O G I E S
CAPABILITIESD I S C O V E R Y T E C H N O L O G I E S
CON
LFU
ENCE
DIS
COVE
RY T
ECH
NO
LOG
IES
| CA
PABI
LITI
ES
Leaders in biochemistry and mechanistic enzymology, our senior team has access to a suite of capabilities and technologies enabling: • Drug:Target interaction • Enzyme:Inhibitor mechanisms • Direct binding kinetics • Compound mechanism of action
Con�uence o�ers a spectrum of cell and molecular biology capabilities: • Identi�cation of biologically important signal transduction pathways • Quantitation of e�cacy and selectivity • Understanding safety issues linked to pathways • De-convolution to isolate pathway nodes • Evaluation of multiple targets within the pathway • Identi�cation of key pathway point(s) for therapeutic intervention • Target validation, cloning, expression, and puri�cation • Custom assay development • High-throughput screening
Our team delivers when “OFF the SHELF” is not an option: • Assay development, optimization, and validation • Multiplex technology platforms and instrumentation • Complex data analysis • Specialty screens for preclinical technical application • Trouble shooting and problem solving
Our team provides clients with the expertise to: • Identify target, mechanism, and disease biomarkers • Select the appropriate biomarkers for a drug discovery program • Execute biomarker assay design, development, validation, and interpretation for pre-clinical and clinical studies • Seamless assay transfer from pre-clinical to clinical studies
Our medicinal and computational chemists are experts in designing and delivering novel chemical entities through: • Schrödinger® enabled computational drug design • High throughput hit prioritization • Chemical series prioritization • Structure activity relationship generation • Custom synthesis